• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Ophthalmology

Rho kinase inhibitor safely reduces intraocular pressure

byAndrew Bishara
June 28, 2013
in Ophthalmology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

Image: PD Human eyesight with glaucoma

1. Various concentrations of Rho kinase inhibitor K-115 decreased IOP after administration compared to placebo (p<0.05). 

2. The only significant side effect was conjunctival hyperemia, which was painless and resolved within 6 hours.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Rho kinase inhibitors are a promising new group of glaucoma medications that alter trabecular meshwork, the tissue that is the most likely cause of ocular hypertension. This phase 1 randomized controlled trial demonstrates safety of the Rho kinase inhibitor K-115 and its ability to decrease intraocular pressure (IOP). IOP appears to decrease in a dose-dependent response and lasts for approximately 24 hours, which would make K-115 a reasonable therapeutic agent. While a clinically significant decrease in IOP was observed, the repeat-administration trial showed an insignificant IOP decrease compared to placebo, demonstrating the need for a larger study with more participants. The large magnitude of IOP decrease with the placebo is surprising, and requires further investigation. An additional limitation is that a noncontact tonometer was used to measure IOP. While the study was consistent in only using noncontact tonometry, controversy remains regarding its reliability compared to the gold standard of contact tonometry. Nonetheless, the efficacy of this Rho kinase inhibitor in humans is promising. Further studies are needed to gauge the value of K-115 in glaucoma patients and how K-115 may work synergistically with other antiglaucoma medications to reduce IOP.

Click to read the study in JAMA Ophthalmology

Relevant Reading: Effects of Rho-Associated Protein Kinase Inhibitor Y-27632 on Intraocular Pressure and Outflow Facility

RELATED REPORTS

Monthly brolucizumab is noninferior to aflibercept in treating recalcitrant wet age-related macular degeneration

Serum lipid levels are positively associated with intraocular pressure

Faricimab noninferior to aflibercept for treatment of neovascular age-related macular degeneration

In Depth [randomized study]: A group of 50 healthy volunteers who had no ocular disease was identified. Subjects were randomized to the placebo or K-115, a Rho kinase inhibitor, group. Treatment was administered topically in varied concentrations (0.05%, 0.1%, 0.2%, 0.4%, 0.8%) and in either a single-administration trial or repeat-administration trial. The latter involved administration of K-115 or placebo twice daily for seven days. Slit lamp exams, including IOP measurement, were performed before administration and at several points up to 47 hours post-administration of the last dose. Eye exams were used to check for any drug reactions and serum lab tests were completed. In the single-administration trial, the IOP reduction in the 0.05%, 0.4%, and 0.8% groups was significant compared to placebo 2 hours after administration (p<0.05). In the repeat-administration trial, IOP reduction lasted for 24 hours with maximal IOP reduction occurring 1-2 hours after administration. While IOP reduction was significant at that time point within each treatment group, there was no significant difference between the IOPs of the treatment groups and placebo group. In terms of safety, conjunctival hyperemia was the most common side effect, occurring in 13-100% of patients treated with K-115 but in none given placebo. This finding resolved usually within 5-6 hours. There were no effects on visual acuity.

By Swarup Swaminathan and Andrew Bishara

More from this author: Visual impairment is increasing among American adults, Contact lens sensor allows for continuous intraocular pressure monitoring, Conventional Wnt signaling pathway is a potential new target for glaucoma therapeutics, Inhibition of molecular signaling in injured cornea hastens cell migration and wound closure, New point of care test highly sensitive and specific for adenoviral conjunctivitis, Argus II retinal prosthesis significantly improves spatial vision in blind patients, Artificial cornea is well retained in patients with ocular surface disease, High prevalence of undiagnosed glaucoma in West Africa, Interferon therapy is superior to methotrexate for uveitis

© 2013 2minutemedicine.com. All rights reserved. No works may be reproduced without written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT. Content is produced in accordance with fair use copyrights solely and strictly for the purpose of teaching, news and criticism. No benefit, monetary or otherwise, is realized by any participants or the owner of this domain. 

Tags: glaucomahyperemiaintraocular pressureOphthalmologyrho kinasevisual acuity
Previous Post

Surgical learning curve: factors in minimally invasive mitral valve surgery

Next Post

Intake of fish fatty acids associated with lower risk of breast cancer

RelatedReports

Nonpowder gun-related pediatric eye injuries on the rise
Ophthalmology

Monthly brolucizumab is noninferior to aflibercept in treating recalcitrant wet age-related macular degeneration

June 7, 2022
Nonpowder gun-related pediatric eye injuries on the rise
Ophthalmology

Serum lipid levels are positively associated with intraocular pressure

May 10, 2022
Blindness and visual impairment decreasing worldwide
Chronic Disease

Faricimab noninferior to aflibercept for treatment of neovascular age-related macular degeneration

March 9, 2022
Blindness and visual impairment decreasing worldwide
Chronic Disease

Faricimab may improve visual acuity in patients with diabetic macular edema

March 8, 2022
Next Post
Intake of fish fatty acids associated with lower risk of breast cancer

Intake of fish fatty acids associated with lower risk of breast cancer

Emerging coronavirus found to spread in healthcare facilities

2 Minute Medicine Rewind June 24 - June 30

Study shows poor follow up of children with high blood pressure

Study shows poor follow up of children with high blood pressure

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.